Special Issue "Cardiometabolic Challenges-Present and Future"

A special issue of Metabolites (ISSN 2218-1989).

Deadline for manuscript submissions: 30 November 2020.

Special Issue Editors

Prof. Dr. Manfredi Rizzo
Website
Guest Editor
Section Editor
1. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy
2. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, 29208 SC, USA
Interests: diabetes; cardiovascular prevention; lipids and lipoproteins; metabolic syndrome
Prof. Dr. Anca Pantea Stoian
Website
Guest Editor
Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Str., 050474, Bucharest, Romania
Interests: diabetes; nutrition; metabolic diseases; chronic kidney disease

Special Issue Information

Dear Colleagues,

Cardiovascular diseases represent the first cause of morbidity and mortality in most industrialised countries, and metabolic alterations are so strictly linked that is common to talk about the two as a whole, referring to them as cardiometabolic. Due to increasing sedentary habits and profound life habit changes, the cardiometabolic risk is an emerging problem in the entire planet, and it is crucial to identify the right targets of prevention and therapy. This Special Issue is dedicated to reviewing the current practical aspects of insulin resistance, and type-2 diabetes, atherogenic dyslipidemia, PCSK9 inhibition, hypertension, overweight and obesity, uric acid alteration, obstructive sleep apnea, chronic kidney disease, polycystic ovary syndrome ,and non-alcoholic fatty liver disease and will also highlight the most critical targets of prevention and therapy for an effective reduction of cardiometabolic risk. The triumvirate of metabolic syndrome, chronic kidney diseases, and coronary heart disease has as its mainstay oxidative stress and chronic inflammation. In the light of the determinations of new markers involved in this triad, as well as the new therapies focusing on cardio-renometabolic components, this edition aims to bring a modern approach to all innovations in this field.

Prof. Dr. Manfredi Rizzo
Prof. Dr. Anca Pantea Stoian
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic syndrome
  • cardiometabolic risk
  • cardio-renometabolic markers
  • insulin resistance
  • type-2 diabetes
  • chronic kidney disease

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Evolution of Inflammatory and Oxidative Stress Markers in Romanian Obese Male Patients with Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy: One Year Follow-Up
Metabolites 2020, 10(8), 308; https://doi.org/10.3390/metabo10080308 - 28 Jul 2020
Abstract
Geography is one of the key drivers of the significant variation in the etiopathogenic profile and prevalence of type 2 diabetes mellitus (T2DM) and obesity, therefore geographically based data are fundamental for implementing the appropriate interventions. Presently, the selection criteria of T2DM and [...] Read more.
Geography is one of the key drivers of the significant variation in the etiopathogenic profile and prevalence of type 2 diabetes mellitus (T2DM) and obesity, therefore geographically based data are fundamental for implementing the appropriate interventions. Presently, the selection criteria of T2DM and obesity patients for laparoscopic sleeve gastrectomy (LSG) have not reached a worldwide consensus—highlighting the need for sharing experts’ guidance in the preoperative evaluation, choice of the interventional procedure, perioperative management and patient long-term care. The aim of the current study was to evaluate the impact of LSG on T2DM (T2DM) remission in Romanian obese male patients, based on a multiparametric, prospective investigation. We have conducted a randomized controlled study on 41 obese male participants with the body mass index (BMI) ≥ 30 kg/m2, aged 30–65 years, which were randomly divided in two study groups: one receiving conventional treatment and the second undergoing LSG. The clinical and anthropometrical parameters, resting metabolic rate, general biochemical status, adipocytes profile, gastrointestinal hormones levels, proinflammatory, oxidant and antioxidant profiles were determined at three time points: V1 (baseline), V2 (after six months) and V3 (after 12 months). Glycated hemoglobin (HbA1c), blood glucose levels, BMI, weight, visceral fat level, HDL-cholesterol, incretin hormones, proinflammatory and the oxidative stress status were significantly improved in the LSG versus conventional treatment group. This is the first study reporting on the evaluation of metabolic surgery impact on Romanian obese male patients with T2DM. Our results confirm that LSG could contribute to T2DM remission in patients with diabesity, but this beneficial effect seems to be critically influenced by the duration of T2DM rather than by the obesity status. Our results show that, in addition to the parameters included in the prediction algorithm, the proinsulin levels, proinsulin/insulin ratio and the visceral fat percentage could bring added value to the assessment of metabolic status. Full article
(This article belongs to the Special Issue Cardiometabolic Challenges-Present and Future)
Open AccessArticle
Dyslipidemia: A Trigger for Coronary Heart Disease in Romanian Patients with Diabetes
Metabolites 2020, 10(5), 195; https://doi.org/10.3390/metabo10050195 - 14 May 2020
Cited by 2
Abstract
Previous studies have reported age and gender disparities in the occurrence and therapeutic approach of dyslipidemia and (or) coronary heart disease (CHD) in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate these differences in Romanian patients with T2DM. A cross-sectional, [...] Read more.
Previous studies have reported age and gender disparities in the occurrence and therapeutic approach of dyslipidemia and (or) coronary heart disease (CHD) in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate these differences in Romanian patients with T2DM. A cross-sectional, observational, retrospective study was conducted using the medical records of T2DM patients who attended the outpatient facility of the Internal Medicine Clinic of the Clinical Emergency Hospital of Bucharest, Romania for routine check-ups in a six-month period. We analyzed the records of 217 diabetic patients (mean age 69 ± 11 years; 51.15% women). We found no significant gender differences in the occurrence of dyslipidemia, CHD or CHD + dyslipidemia or in terms of statin prescription. However; patients aged 65 years or older were significantly more affected by dyslipidemia, CHD or CHD + dyslipidemia, versus subjects aged <65 years. Further, they were more likely to be prescribed statin therapy (p < 0.0001 for all). Statins were prescribed to 67.24% of the patients with dyslipidemia; 61.01% of the subjects with CHD; and to 91.48% of the patients who had both conditions. e recorded no gender differences in the occurrence of CHD and (or) dyslipidemia in Romanian T2DM patients. Patients aged 65 years or older had a higher prevalence of CHD and/or dyslipidemia, and were more likely to be prescribed statins, versus younger counterparts. However, many T2DM patients with CHD and (or) dyslipidemia were undertreated: Nearly 33% of the subjects with dyslipidemia, and nearly 40% of the ones with CHD were not prescribed statins. Full article
(This article belongs to the Special Issue Cardiometabolic Challenges-Present and Future)
Show Figures

Figure 1

Back to TopTop